Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art

Frontiers in Cardiovascular Medicine

Volumn 2, Issue , 2015, Pages

  Thaler, Johannes ^a   Pabinger, Ingrid ^a   Ay, Cihan ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

anticoagulation; deep vein thrombosis; pulmonary embolism; secondary prevention; venous thromboembolism

Indexed keywords

EID: 85008422715     PISSN: None     EISSN: 2297055X     Source Type: Journal    
DOI: 10.3389/fcvm.2015.00030     Document Type: Review

References (62)

1. Abildstrom SZ, Rasmussen S, Rosen M, Madsen M. Trends in incidence and case fatality rates of acute myocardial infarction in Denmark and Sweden. Heart (2003) 89(5):507–11.10.1136/heart.89.5.50712695453
2. Ferrieres J, Cambou JP, Ruidavets JB, Pous J. Trends in acute myocardial infarction prognosis and treatment in southwestern France between 1985 and 1990 (the MONICA project-Toulouse). Am J Cardiol (1995) 75(17):1202–5.10.1016/S0002-9149(99)80762-07778539
3. Ellekjaer H, Holmen J, Indredavik B, Terent A. Epidemiology of stroke in innherred, Norway, 1994 to 1996. Incidence and 30-day case-fatality rate. Stroke (1997) 28(11):2180–4.10.1161/01.STR.28.11.21809368561
4. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet (2005) 365(9465):1163–74.10.1016/S0140-6736(05)71880-815794972
5. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost (2007) 5(4):692–9.10.1111/j.1538-7836.2007.02450.x17367492
6. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet (2012) 379(9828):1835–46.10.1016/S0140-6736(11)61904-122494827
7. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med (2004) 140(11):867–73.10.7326/0003-4819-140-11-200406010-0000715172900
8. Buller HR, Sohne M, Middeldorp S. Treatment of venous thromboembolism. J Thromb Haemost (2005) 3(8):1554–60.10.1111/j.1538-7836.2005.01414.x16102019
9. Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev (2006) (1):CD001367.10.1002/14651858.CD001367.pub3
10. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 361(24):2342–52.10.1056/NEJMoa0906598
11. Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med (2013) 369(15):1406–15.10.1056/NEJMoa130663823991658
12. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 369(9):799–808.10.1056/NEJMoa130250723808982
13. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2010) 369(9):799–808.10.1056/NEJMoa130250723808982
14. van Es N, Coppens M, Schulman S, Middeldorp S, Buller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood (2014) 124(12):1968–75.10.1182/blood-2014-04-57123224963045
15. van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost (2013) 12(3):320–8.10.1111/jth.1248524330006
16. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism. Circulation (2006) 113(4):577–82.10.1161/CIRCULATIONAHA.105.59259216432055
17. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J (2014) 35(43):3033–69, 69a–69k.10.1093/eurheartj/ehu283
18. Konstantinides S, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, et al. [2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism]. Kardiol Pol (2014) 72(11):997–1053.10.5603/KP.2014.0211
19. Chan CM, Woods C, Shorr AF. The validation and reproducibility of the pulmonary embolism severity index. J Thromb Haemost (2010) 8(7):1509–14.10.1111/j.1538-7836.2010.03888.x20403093
20. Donze J, Le Gal G, Fine MJ, Roy PM, Sanchez O, Verschuren F, et al. Prospective validation of the pulmonary embolism severity index. A clinical prognostic model for pulmonary embolism. Thromb Haemost (2008) 100(5):943–8.18989542
21. Vanni S, Nazerian P, Pepe G, Baioni M, Risso M, Grifoni G, et al. Comparison of two prognostic models for acute pulmonary embolism: clinical vs. right ventricular dysfunction-guided approach. J Thromb Haemost (2011) 9(10):1916–23.10.1111/j.1538-7836.2011.04459.x21819540
22. Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med (2005) 172(8):1041–6.10.1164/rccm.200506-862OC16020800
23. Guyatt GH, Akl EA, Crowther M, Schunemann HJ, Gutterman DD, Zelman Lewis S. Introduction to the ninth edition: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest (2012) 141(2 Suppl):48S–52S.10.1378/chest.11-228622315255
24. Ruiz-Gimenez N, Suarez C, Gonzalez R, Nieto JA, Todoli JA, Samperiz AL, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE registry. Thromb Haemost (2008) 100(1):26–31.10.1160/TH08-03-019318612534
25. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the national registry of atrial fibrillation (NRAF). Am Heart J (2006) 151(3):713–9.10.1016/j.ahj.2005.04.01716504638
26. Harenberg J, Hentschel VA, Du S, Zolfaghari S, Kramer R, Weiss C, et al. Anticoagulation in patients with impaired renal function and with haemodialysis. Anticoagulant effects, efficacy, safety, therapeutic options. Hamostaseologie (2015) 35(1):77–83.10.5482/HAMO-14-08-003625405246
27. Bounameaux H, de Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J Thromb Haemost (2004) 2(4):551–4.10.1111/j.1538-7933.2004.00648.x
28. Harenberg J. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes. J Thromb Haemost (2004) 2(4):547–50.10.1111/j.1538-7933.2004.00647.x
29. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med (2013) 368(8):699–708.10.1056/NEJMoa120754123216615
30. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 363(26):2499–510.10.1056/NEJMoa100790321128814
31. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 366(14):1287–97.10.1056/NEJMoa111357222449293
32. Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, et al. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood (2009) 114(5):952–6.10.1182/blood-2009-02-20792819439733
33. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest (2012) 141(2 Suppl):7S–47S.10.1378/chest.1412S3
34. Kearon C, Ginsberg JS, Anderson DR, Kovacs MJ, Wells P, Julian JA, et al. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost (2004) 2(5):743–9.10.1046/j.1538-7836.2004.00698.x15099280
35. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med (2000) 160(6):769–74.10.1001/archinte.160.6.76910737276
36. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of anticoagulation trial study group. N Engl J Med (1995) 332(25):1661–5.10.1056/NEJM1995062233225017760866
37. Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation (2001) 103(20):2453–60.10.1161/01.CIR.103.20.245311369685
38. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation (2012) 121(14):1630–6.10.1161/CIRCULATIONAHA.109.92521420351233
39. Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. Br J Haematol (2001) 114(3):512–28.10.1046/j.1365-2141.2001.02981.x
40. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet (2003) 362(9383):523–6.10.1016/S0140-6736(03)14111-612932383
41. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA (2005) 293(19):2352–61.10.1001/jama.293.19.235215900005
42. Rintelen C, Pabinger I, Knobl P, Lechner K, Mannhalter C. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost (1996) 75(2):229–32.8815565
43. De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Rossi E, Chiusolo P, et al. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br J Haematol (2001) 113(3):630–5.10.1046/j.1365-2141.2001.02827.x11380448
44. De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med (1999) 341(11):801–6.10.1056/NEJM19990909341110410477778
45. Eichinger S, Pabinger I, Stumpflen A, Hirschl M, Bialonczyk C, Schneider B, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost (1997) 77(4):624–8.
46. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet (2010) 376(9757):2032–9.10.1016/S0140-6736(10)60962-221131039
47. Pabinger I, Ay C. Risk of venous thromboembolism and primary prophylaxis in cancer. Should all patients receive thromboprophylaxis? Hamostaseologie (2011) 32(2):132–7.10.5482/ha-117321822526
48. Konigsbrugge O, Pabinger I, Ay C. Risk factors for venous thromboembolism in cancer: novel findings from the vienna cancer and thrombosis study (CATS). Thromb Res (2014) 133(Suppl 2):S39–43.10.1016/S0049-3848(14)50007-224862144
49. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med (2000) 343(25):1846–50.10.1056/NEJM20001221343250411117976
50. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood (2002) 100(10):3484–8.10.1182/blood-2002-01-010812393647
51. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol (2015) 33(6):654–6.10.1200/JCO.2014.59.735125605844
52. Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost (2013) 11(1):56–70.10.1111/jth.12070
53. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med (2003) 349(2):146–53.10.1056/NEJMoa02531312853587
54. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med (2002) 162(15):1729–35.10.1001/archinte.162.15.172912153376
55. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med (2006) 119(12):1062–72.10.1016/j.amjmed.2006.02.02217145251
56. van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost (2014) 12(3):320–8.10.1111/jth.1248524330006
57. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost (1999) 82(2):610–9.
58. Kher A, Bauersachs R, Nielsen JD. The management of thrombosis in pregnancy: role of low-molecular-weight heparin. Thromb Haemost (2007) 97(4):505–13.17393011
59. Schaefer C, Hannemann D, Meister R, Elefant E, Paulus W, Vial T, et al. Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost (2006) 95(6):949–57.16732373
60. Lopez-Jimenez L, Montero M, Gonzalez-Fajardo JA, Arcelus JI, Suarez C, Lobo JL, et al. Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica (2006) 91(8):1046–51.16885044
61. Oger E, Bressollette L, Nonent M, Lacut K, Guias B, Couturaud F, et al. High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients. Thromb Haemost (2002) 88(4):592–7.12362229
62. Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J (2013) 11(1):21.10.1186/1477-9560-11-2124053656